上海交通大学学报（医学版）

›› 2010, Vol. 30 ›› Issue (10): 1288-.doi: 10.3969/j.issn.1674-8115.2010.10.025

• 综述 • 上一篇    下一篇

CD40、CD40L和sCD40在B细胞恶性血液肿瘤中的作用

沈维娜, 综述；李军民, 审校   

  1. 上海交通大学 医学院附属瑞金医院血液科, 上海 200025
  • 出版日期:2010-10-25 发布日期:2010-10-27
  • 作者简介:沈维娜（1985—）, 女, 硕士生；电子信箱: shenlcm@yahoo.com.cn。

Roles of CD40, CD40L, and sCD40 in B-cell hematologic malignancies

SHEN Wei-na, reviewer；LI Jun-min, reviser   

  1. Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2010-10-25 Published:2010-10-27

PDF (PC)

1479

摘要：

CD40、CD40L和sCD40作为重要的信号分子，在诱导抗原呈递细胞、T细胞的活化与肿瘤免疫中发挥着重要作用。该文探讨这三种分子在急性淋巴细胞白血病、急性髓细胞白血病、慢性淋巴细胞白血病、淋巴瘤和多发性骨髓瘤等疾病中的发病机制，以及多种CD40结合药物，如CD40L三聚体（CD40LT）、CD40单抗和CD40L阳性细胞目前作为免疫治疗药物在血液肿瘤治疗中的临床意义。

关键词: CD40, CD40L, sCD40, 血液肿瘤

Abstract:

CD40, CD40L, and sCD40, as important signaling molecules, play a great role in inducing antigen-presenting cells, T cell activation, and tumor immunology. This paper investigates these three signaling molecules in pathogenesis of acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, lymphoma, and multiple myeloma, and clinical significance of using immunologic CD40 bound drugs, such as CD40L trimer, CD40 monoantibody, and CD40L positive cell, in treating hematologic malignancies.

Key words: CD40, CD40L, sCD40, hematologic malignancies